The tumor suppressor p14arf interacts, in response to oncogenic signals, with the p53 E3-ubiquitin ligase HDM2, thereby resulting in p53 stabilization and activation. In addition, it also exerts tumor-suppressive functions in p53-independent contexts. The activities of p14arf are regulated by the nucleolar chaperone nucleophosmin (NPM1), which controls its levels and cellular localization. In acute myeloid leukemia with mutations in the NPM1 gene, mutated NPM1 aberrantly translocates in the cytosol carrying with itself p14arf that is subsequently degraded, thus impairing the p14arf-HDM2-p53 axis. In this work we investigated the complex between these two proteins by means of NMR and other techniques. We identified a novel NPM1-interacting motif in the C-terminal region of p14arf, which corresponds to its predicted nucleolar localization signal. This motif recognizes a specific region of the NPM1 N-terminal domain and, upon binding, the two proteins form soluble high molecular weight complexes. By NMR, we identified critical residues on both proteins involved in the interaction. Collectively, our data provide a structural framework to rationalize the overall assembly of the p14arf-NPM1 supramolecular complexes. A number of p14arf cancer-associated mutations cluster in this motif and their effect on the interaction with NPM1 was also analyzed.
Introduction
The human p14arf tumor suppressor protein (p19arf in mice) arises from an alternative reading frame transcription of the Ink4a gene, also encoding a second tumor suppressor, the p16
Ink4a protein [1, 2] . The two proteins are transcribed from different promoters and share two of their three exons. This gene is frequently altered in tumors. Alterations include the loss of the Ink4b-ArfInk4a locus or of only the Ink4a exon Ib, which is specific for p14arf. Moreover, several mutations at exon II, encoding the C-terminal half of p14arf, were described [3, 4] . They range from frameshift mutations, with the appearance of premature stop codons, to several missense mutations. The tumor spectrum of p14arf mutations is varied and includes: anaplastic meningioma, angiosarcoma, bladder adenocarcinoma, breast cancer, chronic myelogenous leukemia, colorectal carcinoma, T-cell acute lymphoblastic leukemia, and many others [5] . The tumor-suppressive importance of this protein is confirmed by the spontaneous development of tumors in mice knocked-out for the p14arf homologue p19arf as early as 8 weeks after birth [6] .
P14arf is expressed at low levels and localized in the nucleoli of unstressed cells. However, its expression is strongly upregulated by oncogenic signals including E1A, Ras, c-Myc, E2F-1 and v-Abl [7] . Its classical activity as a tumor suppressor consists in the stabilization of p53 via a p14arf/human double minute 2 (HDM2)/p53 axis. HDM2 is the main E3-ubiquitin ligase of p53 and maintains p53 levels low in unstressed cells. When prompted by oncogenic signals, p14arf interacts with HDM2, liberating p53 from HDM2-mediated translocation and ubiquitination in the cytoplasm [8] .
More recently a number of p53-independent tumor-suppressive functions have also been ascribed to p14arf [2] .
Among the p14arf interaction partners, much interest has been devoted to nucleophosmin (NPM1). NPM1 is a nucleus-cytoplasmic shuttling chaperone, mainly localized in nucleoli, that plays crucial activities in ribosome maturation and export, DNA damage response, centrosome duplication and response to stress stimuli [9] [10] [11] . NPM1 is frequently overexpressed in solid tumors and is the subject of chromosomal translocations and mutations in hematological malignancies. Notably, NPM1 is the most frequently mutated protein in acute myeloid leukemia (AML) [12] . Mutations are always heterozygous and consist in frameshift insertions at the terminal exon of the gene, resulting in the unfolding of the C-terminal nucleic acid binding domain [13] , the loss of the nucleolar localization signal (NoLS) and the appearance of a novel nuclear export signal (NES). Therefore, mutated NPM1 is aberrantly and stably delocalized in the cytosol of leukemic blasts [12] .
In unstressed cells, NPM1 colocalizes with the tumor suppressor p14arf in the nucleolus, where they are found in high molecular weight complexes [14] . There is evidence that NPM1 sequesters p14arf into the nucleolus, impairing p14arf-HDM2 association and inhibiting p14arf-dependent p53 activation [15, 16] . In response to cellular stress both NPM1 and p14arf relocalize in the nucleoplasm, where they may compete for binding to HDM2 [17] . Thus, the p14arf nucleoplasmic interaction with HDM2, that regulates the p53 cell-cycle checkpoint, depends on NPM1 localization. This is consistent with the loss of p14arf in leukemic blasts, due to its cytoplasmic translocation played by mutated NPM1, and subsequent degradation [18] . This mechanism leads to the inactivation of the p14arf/ HDM2/p53 tumor suppressor pathway in the blasts despite p53 being always wild-type in this type of leukemia [19] . Therefore, the p14arf/NPM1 interaction surface has been proposed as a drug target for the treatment of AML with NPM1 mutation [20] . In fact, interfering with this interaction may rescue p14arf levels in leukemic blasts and activate the p53 pathway.
The interaction between mouse p19arf and NPM1 has been recently investigated [21] . It was shown that the N-terminal domain of NPM1 interacts with a p19arf-derived peptide consisting of the first six Nterminal residues. Previously, the structural properties of a peptide resembling the first 37 residues of p19arf were also determined, showing that it is intrinsically unstructured but able to form fibrillar-like structures when in complex with its HDM2-interacting epitope [22, 23] .
We decided to further investigate this interaction using, for the first time, human full-length p14arf (Fig. 1A) . We show that isolated p14arf forms aggregates through its N-terminal region and that the NPM1 N-terminal domain (residues 16-123; Fig. 1A ) exerts a chaperone activity against this phenomenon. Our data also indicate that the two proteins form soluble supramolecular complexes upon binding. Importantly, these are mediated by a second region of p14arf, in addition to the N-terminal segment, which we show to interact with the NPM1 N-terminal domain. This novel NPM1-interacting region is located in the Cterminal half of the protein, is rich in arginine residues and corresponds to the predicted NoLS of p14arf. We identified the residues involved on both sides by fluorescence and solution NMR spectroscopies. Importantly, this novel interaction region of p14arf is frequently deleted or mutated in cancer; therefore, we also analyzed the effect of p14arf cancer-associated mutations on the interaction with NPM1. We suggest that the NPM1 surface we have characterized here may be considered as a drug target in AML.
Results

Structural analysis of full-length p14arf
Structural information available so far on p14arf (Fig. 1A) , or its mouse homologue p19arf, is limited to the first 37 residues of the reference sequence. This segment of the protein is intrinsically disordered and able to interact with HDM2, forming fibril-like high molecular weight assemblies [22, 23] . Figure 1B shows a preliminary bioinformatics analysis on the p14arf sequence, conducted using several order/disorder predictors. Interestingly, all of them suggest the presence of ordered regions in the N-terminal end of the sequence. To verify whether the N-terminal half of p14arf is indeed structured in the context of the entire protein, we expressed and purified the fulllength construct. First, we analyzed this protein construct by far UV CD. Figure 1C ,D show the CD spectrum of p14arf and its thermal denaturation, respectively. The shape of the spectrum is that typical of unstructured proteins, and the thermal denaturation profile suggests the absence of cooperative transitions from folded to unfolded species. However, a propensity to adopt helical structure in the presence of trifluoroethanol was also observed (Fig. 1C) , partly consistent with PSIPRED secondary structure predictions that indicate the presence of alpha and beta structured regions in the N-terminal half of the protein (Fig. 1B) . This behavior is also consistent with previous results obtained with the 37 aa N-terminal peptide from mouse p19arf [22] . Fig. 1 . Domain organization and analysis of p14arf secondary structure and disorder (A) p14arf consists of 132 residues; here the predicted NoLS (residues 84-103) is highlighted in green. Also shown, in cyan, the N-terminal tail of the protein, which was previously shown to interact with NPM1. NPM1 consists of a methionine-rich N-terminal tail (residues 1-15), a N-terminal domain (NPM1-Nter; 16-123), a central unstructured domain (residues 124-242) and a C-terminal nucleic acid binding domain (residues 243-294). The NES, nuclear localization signals (NLS) and the two tryptophan residues forming the NoLS are also highlighted. (B) Primary structure of human p14arf (132 residues). The underlined sequence corresponds to the putative NoLS as predicted by the NoD algorithm. Residues in red within this region are those that are found mutated in human cancers. Shown are predictions of protein disorder obtained with six different algorithms. (o) Stands for ordered and (d) for disordered residue. A secondary structure propensity prediction as calculated by PSIPRED is also shown, where (e) stands for strand, (h) stands for helix and (c) stands for coil. Two algorithms (ANCHOR and MORF-CHIBI) predict sites in intrinsically disordered protein prone to undergo interaction with globular proteins coupled to disorder-to-order transition: (n) stands for nonbinding while (b) stands for binding. As to the MORF-CHIBI prediction, residues with a MCW score higher than 0.75 were considered as binding prone. (C) CD spectra of full-length p14arf in the absence (black line) or in the presence of 20% (red) or 30% (blue) trifluoroethanol. (D) Thermal denaturation profile of full-length p14arf following the CD signal at 222 nm.
The structural and dynamic properties of p14arf were investigated by NMR spectroscopy. At the protein concentration necessary for NMR analysis (100 lM), we observed a remarkably low solubility and abundant precipitation when the protein was in a nondenaturing buffer. Therefore, we analyzed p14arf in 20 mM phosphate buffer containing 4 M urea, a condition that we found sufficient to keep the protein in solution.
1 H-and 13 C-detected triple resonance NMR experiments, suitable for sequence-specific resonance assignment, were recorded on a sample of 13 C, 15 Nlabeled p14arf. Most of the crosspeaks arising from the N-terminal part of p14arf, comprising residues 1-56, were not detected in the triple resonance experiments and could not be assigned. Of the remaining 76 residues in the region between Gln57 and Gly132, 75 residues were assigned including 12 prolines ( Fig. 2A) . The loss of signal at the N-terminal region of p14arf suggests that this region is involved in the aggregation of the protein. Moreover, even in the moderately denaturing conditions of this experiment, p14arf could be in equilibrium between the free monomeric protein and soluble aggregates, resulting in signal disappearance in the N-terminal region due to either relaxation broadening or exchange broadening. The longitudinal (R 1 ), and transverse (R 2 ) 15 N-amide relaxation rates (Fig. 2B) , the 15 N-nuclear overhauser effect (NOE; Fig. 2C ) and the neighbor-corrected secondary structure propensity values calculated from the backbone chemical shifts (Fig. 2D ) all indicate that the C-terminal fragment 57-132 of p14arf is intrinsically unstructured and does not have any secondary structure propensity in solution.
Notably, p14arf had been previously reported to be able to form oligomers, when ectopically overexpressed in H1299 cells [24] . Therefore, to get further insight into the aggregation propensity of p14arf in the absence of urea we employed a zero-angle light scattering (turbidity) assay. Figure 2E shows a tendency for a diluted sample of p14arf (0.3 lM) to aggregate when the temperature increases from 20°C to higher values. Then, we measured the turbidity at 37°C and at varying protein concentrations, showing that the aggregation propensity is concentration dependent (Fig. 2F) . It is known that the N-terminus of the p14arf mouse homologue p19arf interacts with the N-terminal domain of NPM1 (residues 16-123; hereby NPM1-Nter) [21] and that NPM1-Nter displays molecular chaperone activity on several proteins [25] . Therefore, we checked whether NPM1-Nter exerts chaperone activity on p14arf. This is indeed the case, as shown in Fig. 2G , with a significant decrease in p14arf (0.1 lM) turbidity at 43°C when NPM1-Nter is present at 3-fold excess and a complete loss of aggregation with 5-fold excess.
Structural analysis of the p14arf interaction with NPM1-Nter
We then aimed at characterizing the interaction between p14arf and NPM1-Nter at the residue level by NMR spectroscopy. Given the high tendency of p14arf to aggregate and precipitate in the absence of urea, we sought to perform also these experiments in 20 mM phosphate buffer pH 7.1 containing 4 M urea. Therefore, prior to NMR characterization, we checked whether NPM1-Nter is still folded in this condition. Figure 3A shows static CD spectra of the protein, collected at urea concentrations ranging from 0 to 8 M. These data indicate that NPM1-Nter is folded up to 7 M urea while it starts denaturing only at 8 M urea. To assess whether 4 M urea influenced the oligomerization state of NPM1-Nter, we also performed size exclusion chromatography coupled to multiangle light scattering (SEC-MALS) experiments in 20 mM phosphate buffer pH 7.1 with and without 4 M urea. In the absence of urea (Fig. 3B ), NPM1-Nter elutes as a single peak of 72 kDa MW, which can be attributed to a pentamer (MW of the monomer = 14 kDa). In the presence of 4 M urea, NPM1-Nter still elutes as a single peak with a MW of 56 kDa (Fig. 3C ). The lower MW calculated in 4 M urea might indicate a different quaternary structure, i.e. a tetramer. This is, however, unlikely, given the hydrophobicity of the contact surface at the monomer-monomer interface, and has never been observed [21] . More likely, in the presence of 4 M urea, the monomer-pentamer equilibrium is slightly shifted toward the monomer, even though the pentamer is still the predominant species.
Titration of 15 N-labeled p14arf with unlabeled NPM1-Nter (up to 10 equivalents of NPM1-Nter monomer), in 20 mM phosphate buffer pH 7.1 and 4 M urea, resulted in several p14arf crosspeaks decreasing in intensity and accompanied by minor but measurable chemical shift perturbations in the region of p14arf detectable by NMR (Fig. 4A,B ). An excess of NPM1-Nter was required to observe this effect, indicating the occurrence of weak interactions between the two proteins. This behavior was confirmed by comparing the 15 N relaxation properties of 15 N-p14arf in complex with NPM1-Nter in a 1 : 10 ratio with those of the free protein (Fig. 5) . Notably, the chemical shift variations (Fig. 5A ), the signal intensity ratios ( We also performed the reverse titration in the same mildly denaturing conditions. However, when 15 N-NPM1-Nter was titrated with unlabeled p14arf, the NMR signals of 15 N-NPM1-Nter almost disappeared after addition of as low as 0.1 equivalents of p14arf per NPM1-Nter monomer, likely due to the formation of high molecular weight species at substoichiometric amounts of p14arf.
Analysis of the interaction between NPM1-Nter and the p14arf (84-103) peptide
The finding that an additional, and previously unreported, region of p14arf interacts with NPM1-Nter prompted us to further investigation. NPM1 has been recently reported to recognize arginine-rich motives in its protein partners, which often correspond to their NoLS [26, 27] . Therefore, we checked whether p14arf possesses a NoLS as predicted by the NoD algorithm, which scans a protein sequence in search of local enrichments of positive charges [28] . Interestingly this analysis retrieved a putative NoLS in the same region (84-103) that we identified in p14arf through NMR analysis (Fig. 6A,B) . Moreover, this region is only partially conserved and not predicted to be a NoLS in mouse p19arf (Fig. 6A-C) .
To gain further insight on this interaction, we performed equilibrium fluorescence titrations of a peptide comprising residues 84-103 of p14arf (p14arf-NoLS), tagged with a dansyl group at its N terminus, with NPM1-Nter (Fig. 7A ). This analysis confirmed binding and the data, fitted with Eqn (1) (see Materials and methods), yielded a dissociation constant for the complex of K D = 3.9 AE 0.3 lM (Table 1) .
We further investigated the interaction of p14arf-NoLS with NPM1-Nter by NMR. Differently from full-length p14arf, p14arf-NoLS is highly soluble in aqueous buffer and urea was not required. However, addition of already one equivalent of p14arf-NoLS to 15 N-NPM1-Nter caused the complete loss of protein signals suggesting, once again, the formation of high molecular weight species in slow exchange with the free protein.
This hypothesis was confirmed by SEC-MALS experiments performed in 20 mM phosphate buffer pH 7.1 (Fig. 7B) . A broad peak is observed in the chromatogram of a 1 : 2 mixture of NPM1-Nter:p14arf-NoLS, at a smaller elution volume than free pentameric NPM1-Nter. This peak has a calculated MW of 200-500 kDa, consistent with the formation of large aggregates, while the MW calculated on the peak of pentameric NPM1-Nter increases from 72 kDa to 95 kDa, suggesting that a complex could be formed between a NPM1 pentamer and several p14arf-NoLS peptides. Given the high positive net charge of p14arf-NoLS, we assumed that the nature of its interaction with NPM1-Nter would be mainly electrostatic. Therefore, we repeated the NMR titration experiment under high salt conditions to decrease the electrostatic contribution. Indeed, in 20 mM phosphate buffer pH 7.1 plus 500 mM NaCl, the interaction was sufficiently weakened to allow the NMR signals of NPM1-Nter to be observed upon titration with up to 10 equivalents of p14arf-NoLS (Fig. 8A) . Under these conditions, small chemical shift variations were observed, together with an increase in line-width, indicative of an exchange between the free protein and the aggregated, high molecular weight complex, which could be mapped to the NPM1-Nter structure (Fig. 8B) . From the resulting data, several residues were identified that are putatively involved in the interaction with the peptide. Among them, the largest chemical shift variations were observed for residues 29-32, 37-41, 67-68 and 115 of NPM1-Nter (Fig 8A,B) . Collectively, these residues identify an extended region on the external surface of each NPM1-Nter monomer, which is implicated in p14arf-NoLS binding (Fig. 8C) . and contains two clusters of three arginines each. We next wanted to check whether both clusters are implicated in binding NPM1-Nter. To this purpose we used two modified dansylated peptides and measured their interaction with NPM1-Nter through equilibrium fluorescence spectroscopy. The concomitant mutation into alanine of Arg87, Arg88 and Arg90 in Cluster1 peptide (Table 1) had a significant effect on the affinity of p14arf-NoLS for NPM1-Nter, yielding a K D for the complex 40-fold higher than with wild-type. Likewise, the concomitant mutation of Arg96, Arg98 and Arg99 (Cluster2 peptide) led to an almost 20-fold increase in the K D , showing that also this cluster of arginine residues is important for NPM1-Nter recognition (Table 1) .
Mutational analysis
This NoLS region of p14arf is frequently deleted, or subject to missense mutations in multiple cancers [4, 29] . Most of the identified missense mutations involve the arginine residues of the NoLS. Among them we tested the Arg87Cys, Arg88Gln and Arg90His mutations in the first cluster and the Arg98Leu and Arg99Ser mutations in the second cluster ( Table 1) . Mutation of Arg88 into glutamine led to an increase in the dissociation constant of 2,3-fold, while all other mutations resulted in a K D 1,5-fold higher than wildtype (Table 1) .
Discussion
P14arf is a critical player of the most important tumor-suppressive mechanism in our cells, i.e. the p14arf-HDM2-p53 axis [9] . Therefore, it is not surprising that not only p53 but also p14arf is the frequent target of deletions or mutations in several cancers [4, 29] . In AML with NPM1 mutations, both p14arf and p53 are wild-type but, nevertheless, their tumor-suppressive functions are strongly impaired by the aberrant p14arf translocation in the cytosol due to mutated NPM1 [18, 30, 31] . Unveiling the details of the p14arf-NPM1 interaction may thus have a therapeutic value because a drug capable of interfering with this association may rescue p14arf levels in the leukemic blasts and activate p53-mediated apoptosis or cell-cycle arrest [20] .
Other groups had already shown that the N-terminal segment of the p14arf mouse homologue p19arf interacts with NPM1-Nter [32, 33] . Moreover, a structural investigation of mouse NPM1-Nter in complex with a peptide comprising the first six residues of p19arf (see Fig. 6 ) has been recently published [21] .
Starting from these premises, we further investigated the determinants of this complex. First, we analyzed the structural properties of full-length p14arf in solution. We observed the formation of high molecular weight homo-oligomers of p14arf, likely mediated by its N-terminal end. Interestingly the N-terminal half of mouse p19arf had already been shown to form fibrillike heteropolymers with its cognate peptide from HDM2 [34] . PSIPRED predictions indicated a propensity for p14arf to form two b-strands in the 1-30 region (see Fig. 1 ), which may mediate the formation of homopolymers. We also showed that p14arf aggregates form in a temperature-and concentration-dependent fashion, and that NPM1-Nter acts as a chaperone on p14arf, similarly to what already established with other proteins [25] . Therefore, not only NPM1 is responsible for p14arf nucleolar localization [18] but may also prevent its aggregation within the cell. However, when analyzing their interaction, we observed a tendency of the two proteins to form soluble, high molecular weight complexes even in moderately denaturing conditions. Interestingly, within these complexes, we could identify a previously unknown region of p14arf that interacts with NPM1-Nter, comprised between residues 84-103. This finding captured our attention for several reasons. This region is enriched in arginine residues and it has been recently shown that arginine-rich motives, isolated from proteins such as rpL5, are recognized by NPM1-Nter with the formation of large assemblies resembling liquid-like droplets phase separated from the solvent [26] . Furthermore, the very same region is predicted to be the p14arf NoLS and previous data suggested that it is sufficient to partially drive the nucleolar localization of the protein [35] . As it was previously thought that only the N-terminal region of p14arf mediated the interaction with NPM1 [32, 33] , our data add a new layer of complexity in the formation of this complex. Interestingly, as shown in Fig. 6 , the p14arf-NoLS region of p14arf we identified here is only partially conserved in mouse p19arf. This raises the possibility that, in mice, the N-terminal region of p19arf may suffice for the formation of the assemblies with NPM1. Alternatively, it may also be hypothesized that other regions of p19arf may play the same role as p14arf-NoLS in p14arf. In particular, p19arf is characterized by a 40-residue-long C-terminal extension with respect to p14arf. At the end of this additional region a cluster of five arginines within 10 residues is present (see Fig. 6 ).
Previous analysis conducted with the mouse p19arf (1-6) N-terminal peptide had identified three acidic residues, namely, Asp36, Glu39 and Glu93 that are conserved in human NPM1 and are implicated in the interaction [21] . Our next step was to verify whether the same region of NPM1-Nter is also implicated in the recognition of the p14arf 84-103 region. We showed through fluorescence spectroscopy that the peptide p14arf-NoLS, which encompasses residues 84-103 of p14arf, is able to bind NPM1-Nter with a dissociation constant in the low micromolar range. Then, through the NMR analysis of the complex in high salt conditions, we could identify several residues in NPM1-Nter that show chemical shift variations upon binding. Taken together, these residues identify the p14arf-NoLS interacting region on the external surface of the NPM1-Nter pentamer and comprising residues Tyr29, Phe31, Lys32, Glu37, Glu39, Tyr67, Glu68 and His115 (see Fig. 8 ). This region comprises residue Glu39 and therefore partially overlaps with the one recognizing the p19arf(1-6) peptide, but it is overall more extended. This may be due to the larger size of the p14arf-NoLS peptide (20 residues), which allowed the identification of additional interacting residues in NPM1-Nter.
The p14arf-NoLS peptide contains two stretches of three arginine residues each, between residues 87-90 and 96-99, respectively, whose role in the interaction has been analyzed. Analysis of the Cluster1 and Cluster2 peptides binding to NPM1-Nter (see Table 1) indicated that both of them are implicated in the interaction, with a slightly major contribution played by Cluster1 with respect to Cluster2.
Overall, the experiments we have reported here suggest that the formation of high molecular weight assemblies between NPM1-Nter and p14arf may be more complex than previously thought, and may proceed through several pathways, that may also take place in parallel. Indeed, our data suggest at least three possible scenarios (Fig. 9) . First, p14arf may form homo-oligomers, through its N-terminal end, while interacting also with NPM1-Nter, through its NoLS region (Fig. 9A) . Second, the same p14arf molecule may contact two NPM1-Nter pentamers through its N-terminal and NoLS regions, respectively (Fig. 9B) . Finally, as suggested by our SEC-MALS experiment (see Fig. 7B ) and mutational data, the NoLS region of p14arf may engage at the same time two NPM1-Nter pentamers with its two arginine clusters, leaving the N-terminal end free to interact with itself or with another NPM1-Nter pentamer (Fig. 9C) . Furthermore, it should be noted that full-length NPM1 also contains a central unstructured domain enriched with negatively charged residues, which may themselves interact with p14arf. Therefore, the interaction between the two proteins in the physiological context may be even more intricate.
Once these assemblies are formed within nucleoli, p14arf is sequestered by NPM1 in this compartment in a dormant state. Therefore, to exert its tumorsuppressive functions in the nucleoplasm, p14arf needs to be 'liberated' by its interaction with NPM1-Nter. It is well known that p14arf is upregulated in response to several oncogenic signals [7] and increased levels of p14arf may unbalance the NPM1-p14arf assemblies and favor the release of p14arf from nucleoli. However, an important regulatory role played by NPM1 may also be envisaged. Indeed, NPM1-Nter is phosphorylated at various sites by different kinases, in response to a variety of stress signals [10, 11, 36] . Recent data suggested that the sequential phosphorylation of solvent exposed and buried serine and threonine residues within NPM1-Nter results in a pentamer-to-monomer transition which is coupled to the complete unfolding of the domain [21] . Whenever this happens, the large molecular weight assemblies with p14arf would likely be dissolved thus releasing p14arf in the nucleoplasm (Fig. 9D) . Therefore, NPM1 may act as a switchable guardian of p14arf activity under stress conditions. As NPM1-Nter recognizes several proteins through clustered arginine-rich motives, this model may be also relevant for the interaction of NPM1 with different partners. The p14arf 84-103 NoLS region is also the subject of mutations reported in several cancers, which may introduce stop codons or substitute single residues [4, 29] . Notably, five of six arginine residues in the region are mutated in cancers and we tested the interaction of the corresponding p14arf-NoLS variants with NPM1-Nter (see Table 1 ) [29] . Our data argue against a major effect of these mutations in disrupting the interaction with NPM1-Nter, with increases in the dissociation constant comprised between 1.5-and 2.3-fold. However, an effect played by the mutations on the interaction with full-length NPM1, through its central domain, cannot be excluded at present. Furthermore, even when considering NPM1-Nter only, a modest perturbation in vitro may still have an effect in vivo. For instance, it has been shown that the Arg88Gln mutation, which doubles the p14arf-NoLS-NPM1-Nter dissociation constant (see Table 1 ), caused an ample diffusion of the protein from the nucleoli to the nucleoplasm and the cytoplasm when p14arf was overexpressed in U2-OS cells [29] . Notably, the very same mutations were also shown to be detrimental for the formation of the complex between p14arf and the mitochondrial protein p32, thus impairing the p53-dependent mitochondrial activation of apoptosis played by p14arf [37] . Our findings therefore indicate the need for further in vivo investigation of the effect of p14arf mutations on the interaction with NPM1.
In conclusion, we have provided here novel insight into the NPM1-p14arf interaction. We have identified a previously unknown region of p14arf that is recognized by NPM1-Nter and identified residues that are implicated in binding. These data may facilitate the design of peptidomimetic molecules or small chemicals that interfere with this interaction, to be tested for the treatment of AML and possibly other cancers.
Materials and methods
Protein expression and purification
Human NPM1-Nter (residues 16-123) was expressed and purified as follows. A codon-optimized coding sequence was obtained through gene synthesis (GeneArt, Regensburg, Germany) and subcloned into expression vector pET28a(+) under restriction sites NdeI and BamHI. The resulting plasmid was transformed into Escherichia coli strain BL21 (DE3). Cells were grown in LB medium supplemented with kanamycin at 37°C to A 600~0 .5, at this point 1 mM IPTG was added to induce expression. Cells were further grown overnight at 20°C. , and induced in the same way. After induction, cells were collected by centrifugation, resuspended in lysis buffer (50 mM Hepes pH 7.1, 150 mM NaCl, 6 M GndHCl and 1 mM DTT) plus Protease Inhibitor Cocktail Tablet (Roche) and sonicated. Protein was purified by affinity chromatography (HisTrap FF; GE Healthcare) using a step elution with Buffer A (50 mM Hepes pH 7.1, 150 mM NaCl, 8 M urea and 1 mM DTT) plus Imidazole (15 mM, 300 mM, 500 mM and 1 M). Fractions containing the protein, as showed by SDS/PAGE, were collected, dialyzed against the buffer 20 mM sodium phosphate, pH 7.1, 4 M urea and 1 mM DTT, and concentrated using Amicon Ultra-15 centricons with a 10 kDa cutoff (Merck Millipore). The protein was stored at À20°C. The p14arf NoLS peptide and variants (sequences reported in Table 1 ) were synthesized and dansylated at their N terminus by JPT (Berlin, Germany).
Aggregation and chaperone activity
The aggregation propensity of p14arf was monitored by measuring the zero-angle light scattering with a UV-visible spectrophotometer V650 (Jasco Inc., Easton, MD, USA). Ice-cold p14arf was diluted in Hepes 50 mM pH 7.1 and protein aggregation was monitored over time. For temperaturedependence experiments, protein concentration was set to 0.3 lM and aggregation was monitored at 20, 43 and 60°C. For protein concentration dependence, temperature was set to 37°C and aggregation was monitored with p14arf concentration set to 0.1, 0.3 and 0.7 lM. To assess the chaperone activity of NPM1-Nter, temperature was set to 43°C and p14arf (0.1 lM) aggregation was followed alone and in the presence of three or five excesses of NPM1-Nter.
CD
All CD experiments were performed using a JASCO J710 instrument (Jasco Inc.) equipped with a Peltier apparatus for temperature control.
Spectra were collected using a quartz cell with 1 mm optical path length (Hellma, Plainview, NY, USA) and a scanning speed of 100 nmÁmin À1 . Static spectra of p14arf 
Equilibrium binding assays
The interactions between NPM1-Nter and the p14arf-NoLS and variant peptides were monitored through equilibrium binding experiments. Titrations were performed at 25°C with a FluoroMax-4 spectrofluorometer (Jobin Yvon, Edison, NY, USA) equipped with a water bath apparatus. Experiments were all performed in sodium phosphate buffer 20 mM pH 7.1. Excitation wavelength was 330 nm while emission spectra were recorded in the 350-650 range. Titrations were performed keeping fixed at 5 lM the concentration of the dansylated peptide (p14arf-NoLS and mutants) and varying NPM1-Nter concentration (from 0 to 200/ 400 lM). At least three independent titrations were performed for each peptide and data were globally fitted, within the GRAPHPAD Prism software (GraphPad Software Inc., La Jolla, CA, USA), using Eqn (1): 
NMR experiments
Backbone sequential assignment of p14arf
NMR experiments for the sequence-specific resonance assignment of full-length p14arf were acquired on a sample containing 250 lM [U- of the 102 previously assigned residues were unambiguously reassigned and were included in the analysis. Signal intensity and chemical shift data were collected and analyzed as above.
SEC-MALS experiments
Size exclusion chromatography-MALS experiments were performed at room temperature on NPM1-Nter, either alone or in the presence of two equivalents of p14arf-NoLS peptide, in 20 mM phosphate buffer, pH 7. 
